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 Implication for health policy/practice/research/medical education:
HCC is a global health problem and one of the common fatal malignancies associated with the highest incidence in patients with 
chronic hepatitis and liver cirrhosis. The current study tries to explore HIF-1α expression and trans- activates various genes related to 
HCC aggressiveness. Therefore, the study may recommend for researchers in the ﬁeld of public health, diagnosis and prognosis of HCC.
  c 2011 Kowsar M.P.Co. All rights reserved.
Background: Hypoxia-inducible factor-1 (HIF-1) is a ubiquitously expressed oxygen-regulated 
transcription factor composed of α and β subunits. HIF-1 activates the transcription of vari-
ous genes including those involved in the formation and metastatic growth of hepatocel-
lular carcinoma (HCC).
Objectives: To investigate the levels of hepatic and circulating HIF-1α expression in a range of 
patients with liver disease in order to determine how it can be used in the diagnosis of HCC 
and in establishing prognosis.
Patients and Methods: Total RNA was extracted from a self-controlled HCC and paracancerous 
specimen. HIF-1α mRNA was ampliﬁed by nested RT-PCR and conﬁrmed by sequencing. Tis-
sue HIF-1α was analyzed by immunohistochemistry. The levels of HIF-1α, vascular endothe-
lial growth factor (VEGF), and angiopoietin-2 (Ang-2) expression in the sera of 220 patients 
with liver disease were quantitatively detected by ELISA. 
Results: The positive staining of liver HIF-1α was brown and granule-like and was mainly pre-
sent in the cytoplasm, with lower levels in the nucleus of hepatocytes. Its incidence was 
80% in HCC cells and 100% in paracancerous tissues, with no signiﬁcant diﬀerence in HIF-1α 
expression in relation to tumor number, degree of diﬀerentiation, or hepatitis B surface 
antigen (HBsAg) positivity, but with some correlation between HIF-1α and tumor size. HIF-1α 
expression was detected in the sera of HCC patients at a signiﬁcantly higher level than in 
cases of benign liver disease, with pathological characteristics associated with the levels of 
circulating VEGF and Ang-2 expression, the size of the tumor, and the level of extrahepatic 
metastasis, but not with patients’ gender, age, or alpha-fetoprotein (AFP) levels.
Conclusions: Hepatic HIF-1α expression is associated with the development and prognosis of 
HCC, and circulating HIF-1α level is a useful marker for HCC diagnosis and prognosis.
Hepat Mon. 2011;11(10):821-828. DOI: 10.5812/kowsar.1735143X.771822
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1. Background
Hepatocellular carcinoma (HCC) is one of the most 
common and rapidly fatal malignancies worldwide and 
has been ranked the second highest cancer killer in Chi-
na since the 1990s, particularly in eastern and southern 
areas, including the inshore area of the Yangtze River (1). 
Multiple risk factors are associated with HCC disease eti-
ology, with the highest incidence in patients with chron-
ic hepatitis B virus (HBV) and hepatitis C virus (HCV), 
although other factors such as genetic makeup and en-
vironmental exposure are involved (2-4). As a common 
malignant solid tumor, HCC is characterized by fast inﬁl-
trating growth, early metastasis, high-grade malignancy, 
and poor therapeutic eﬃcacy. It is a highly vascular tu-
mor dependent on neovascularization and is one of the 
most common and rapidly developing malignancies (5, 
6). HCC treatment options are severely limited by the fre-
quent presence of metastases (7). Multistep malignancy 
of HCC progression and multiple gene alterations are 
mostly accompanied by     chronic hepatitis and liver cir-
rhosis (8, 9).
Hypoxia-inducible factor-1 (HIF-1) is a basic helix–loop–
helix Per–Arnt–Sim protein (bHLH-PAS) consisting of α 
and β subunits, and is a key transcription factor regulat-
ing cellular responses to hypoxia (10, 11), and can regulate 
neovascularization and activate the expression of many 
hypoxia-response genes, leading to a close association 
with the HCC ecosystem for tumor growth, inﬁltration, 
metastasis, and prognosis (12, 13). HIF-1α is an oxygen-
dependent protein, which is degraded by poly ubiqui-
tination and proteasomal degradation via the Von Hip-
pel–Lindau tumor suppressor protein under normoxic 
conditions (14-16).  Hepatic HIF-1α  and its expression 
have been previously investigated during the malignant 
transformation of rat hepatocytes (17).
2. Objectives
In the present study, the expression and circulating lev-
els of hepatic HIF-1α were investigated in patients with 
liver disease to prospectively elucidate the relationship 
between HIF-1α level and pathological characteristics, as 
well as the diagnosis and metastasis of HCC.
3. Patients and Methods
3.1. Patient Recruitment
A total of 131 HCC patients, 30 with chronic hepatitis, 22 
with acute hepatitis, and 37 with cirrhosis (Table 1) were 
diagnosed at the Aﬃliated Hospital of Nantong Univer-
sity, Nantong, China, and samples from 27 healthy people 
were obtained from the Nantong Central Blood Bank as 
controls, with negative hepatitis viral markers (hepati-
tis B surface antigen [HBsAg], and anti-HCV antibody), 
normal alanine aminotransferase (ALT) levels, and B-
ultrasonic examination. All samples (5 mL of peripheral 
blood) were collected in the morning and sera were sepa-
rated at once. Serum alpha-fetoprotein (AFP) concentra-
tions exceeding 50 μg/L were taken as a positive result. 
The diagnosis of HCC and viral hepatitis was based on the 
criteria proposed by the Chinese National Collaborative 
Cancer Research Group (18) and at the Chinese National 
Viral Hepatitis Meeting (19), respectively.
3.2. Liver Specimens
The self-controlled HCC and paracancerous specimens 
(2 cm to cancer) were collected from 35 patients who had 
undergone surgery for liver cancer at the Aﬃliated Hos-
pital of Nantong University. The specimens were imme-
diately frozen in liquid nitrogen and kept at -85°C until 
required. The patients included 28 men and 7 women, 
ranging in age from 22 to 70 years. Prior written informed 
consent was obtained from all patients according to the 
World Medical Association Declaration of Helsinki, and 
the study received ethics board approval from the Aﬃli-
ated Hospital of Nantong University. The histologic types 
of all HCC specimens were graded in diﬀerentiation de-
grees as follows: good, 9; moderate, 12; and poor, 14. Of 
these specimens, 20 showed single tumor tubercles and 
the rest multiple; 14 were stage II, 13 were stage III, and 
8 were stage IV. Each specimen was divided into 2 parts 
and analyzed by total RNA extraction and pathologic ex-
amination.
3.3. Total RNA Extraction 
Total RNA was isolated from liver tissues by the gua-
nidine thiocyanate method using the RNAzole reagent 
(Promega, Madison, WI) and puriﬁed as described else-
where. The RNA was dissolved in tromethamine hydro-
chloride buﬀer (10 mmol/L, pH 8.0) containing EDTA, 10 
mmol/L. The concentration of total RNA was assessed by 
optical density measurements at 260 nm in a UV spectro-
photometer and expressed as total RNA micrograms per 
milligram of wet tissue and was then stored at -85°C.
3.4. Synthesis of Complementary DNA (cDNA)
For synthesis of cDNA, the reaction took place in a 20 μL 
HCC a LC a CH a AH a NC a
Patients, No. 131 37 30 22 27
Sex
Male
Female
109
22
16
21
25
5
17
5
12
15
Age, y 33-85 20-82 18-63 24-80 26-69
HBsAg
Positive
Negative
100
31
23
14
22
8
10
12
0
27
AFP, μg/L
≤ 20
21-399 
≥ 400
20
57
54
24
11
2
18
11
1
18
4
0
27
0
0
Table 1. Patient Data in the Present Study
a Abbreviations: AH, acute hepatitis; CH, chronic hepatitis; HCC, hepato-
cellular carcinoma; LC, liver cirrhosis; NC, normal control823
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reaction volume and was performed in a TC412 DNA ther-
mal cycler (Techne, UK). Four micrograms of total RNA 
was denatured ﬁrst in the presence of 1 μL random hex-
amers (Oligo-dT18, 0.5 μg/μL) with the addition of DEPC 
H2O to 12 μL, then in the presence of 4 μL 5× buﬀer, 1 μL Ri-
boLockTM RNAase inhibitor (20 U/μL), and 2 μL dNTP mix 
(10 mmol/L), and ﬁnally with 1 μL RevertAidTM M-MuLV re-
verse-transcriptase (200 U/μL), at 70°C for 5 min, 37°C for 
5 min, 42°C for 60 min, and 70°C for 10 min, and stored at 
-20°C for PCR ampliﬁcation. 
3.5. Ampliﬁcation of Nested RT-PCR
The primers were designed using Premier Primer 
5.0 Software based on the human HIF-1α sequence 
(NM_001530). The primers were synthesized using a syn-
thesizer (Invitrogen, USA). The sequences of the 2 exter-
nal primer pairs used for the initial PCR ampliﬁcation 
were HIF-1α-P1 (sense): 5′-ATACTCAAAG TCGGACAGC-3′ 
(nucleotide [nt] 2386-2404) and HIF-1α-P2 (antisense): 
5′-TT CACCCTGCAGTAGGTTTC-3′ (nt 2833-2852), and the 
size of the ampliﬁed gene fragment was 467 bp. The 
sequences of the 2 internal primer pairs used for the 
second PCR ampliﬁcation were HIF-1α-P3 (sense): 5′-CT-
CATCCAAGAAGCCCTAAC-3′ (nt 2452-2471) and HIF-1α-P4 
(antisense): 5′-TCATAACTGGTCAGCTGTGG-3′ (nt 2781-
2800). The ﬁnal size of the ampliﬁed gene fragment was 
349 bp. PCR ampliﬁcation consisted of initial denatur-
ation at 94°C for 5 min, followed by 94°C for 25 s, 55°C 
for 30 s, and 72°C for 90 s for 30 cycles. The PCR products 
were electrophoresed on 2% agarose gels with ethidium 
bromide staining. The fragment sizes were evaluated 
using PCR markers (Promega) as molecular weight stan-
dards.
3.6. Sequencing of PCR Products
The 349-bp ampliﬁed product of the human HIF-1α gene 
was puriﬁed using a Montage PCR centrifugal ﬁlter de-
vice (Millipore, Billerica, MA) according to the manufac-
turer’s instructions. One microgram of DNA was used 
for preparation of the sequencing reaction and was di-
rectly sequenced using the MegaBACE DNA analysis sys-
tem (MegaBACE DNA sequencer with the DYEnamic ET 
Dye Terminator Cycle Sequencing Kit; Amersham Biosci-
ences, Piscataway, NJ), following the manufacturer’s pro-
tocol. The sequences were edited using the MegaBACE 
Sequence Analyzer, version 3.0 program (Amersham 
Biosciences) and the published HIF-1α gene was aligned 
with the ampliﬁed sequences from our human HCC and 
related paracancerous tissue samples.
3.7. Quantitative Detection of HIF-1α, VEGF and Ang-2 
Levels
The levels of serum HIF-1α and VEGF (R&D systems, 
Abingdon, UK), and Ang-2 (ADL Biotech Dev Co., USA) 
were detected by ELISA in accordance with the manufac-
turer’s instructions. During the procedure, the plate was 
washed according to the routine ELISA method. Concen-
trations were calculated using a standard curve generat-
ed with speciﬁc standards provided by the manufactur-
er. Inter and intra-assay variations were lower than 10%.
3.8. Immunohistochemistry
The Polymer Detection System streptavidin-peroxi-
dase (S-P) kit and positive control were purchased from 
Zhongshan Biotechnology Development Company, Chi-
na. Serial 4-μm–thick paraﬃn sections were sequentially 
treated before application of primary antibodies in the 
following ways: deparaﬃnization, dehydration, endog-
enous peroxidase quenching, and antigen retrieval. An-
tigen retrieval for HIF-1α involved incubation with EDTA 
buﬀer in an autoclave. The sections were incubated with 
the monoclonal HIF-1α antibody (NeoMarkers, UK) at 
room temperature for 1 h. After the sections were washed 
with phosphate-buﬀered saline (PBS), the second anti-
body was added and incubated at room temperature for 
30 min. The slides were then rinsed and the antibodies 
were detected by applying 3,3′-diaminobenzidine (DAB) 
as the chromogen for 5 min and a negative control with 
PBS was used substitute for the primary antibody. Breast 
cancerous tissue was used as an HIF-1α positive control. 
Expression of HIF-1α in 5 randomly selected microscopic 
ﬁelds (×200) was semi-quantitatively evaluated on the 
basis of the percentage of positive cells and classiﬁed as 
follows: when positive cells accounted for less than 10% of 
total cells, negative staining (-); 10–25%, weak staining (+); 
26–50%, moderate staining (++); and > 51%, strong stain-
ing (+++).
3.9. Statistical Analysis
The patients were divided by diagnosis into HCC, acute 
hepatitis, chronic hepatitis, and liver cirrhosis, and 
healthy people served as the controls. Results are ex-
pressed as mean ± standard deviation (SD). Diﬀerences 
between groups were assessed by using a Student’s t test 
or a χ2 test. A P value of 0.05 or less was considered signiﬁ-
cant. Sensitivity and speciﬁcity were calculated accord-
ing to the following formulas: sensitivity = a/ (a + c); and 
speciﬁcity = d/ (b + d), where a = true-positive cases, b = 
false-positive cases, c = false-negative cases, and d = true-
negative cases. Receiver operating characteristic (ROC) 
curves (20) were constructed by calculating the sensitivi-
ties and speciﬁcities at several cutoﬀ points.
4. Results
4.1.Expression of Hepatic HIF-1α in Liver Tissue
The expression and cellular distribution of HIF-1α in 
HCC tissues and comparative analysis with associated 
paracancerous tissues are shown in Figure 1. The positive 
staining of liver HIF-1α was brown and granule-like and 
mainly present in the cytosol, with lower levels in the 
nucleus. Positive cells were well distributed and in signif-
icant numbers in adjacent areas of necrosis and tumor 824
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D
HCC a, No. (%) Para-HCC, No. (%) P value b Z value
HIF-1α positive 28 (80.0) 35 (100) 0.017 0.000
HIF-1α Intensity 0.000 4.728
-
+
++
+++
7 (20)
21 (60)
7 (20)
0 (0)
0 (0)
10 (28.57)
18 (51.43)
7 (20)
Table 2. Comparative Analysis of HIF a-1α Expression Intensity in HCC or Associated Paracancerous Tissues (n = 35)
a Abbreviations: HCC, hepatocellular carcinoma; HIF, hypoxia-inducible factor-1α
b P value vs. the paracancerous tissue group
between them (t = 3.05, P < 0.01). The ﬁnal ampliﬁed frag-
ment of the hepatic HIF-1α gene was 349 bp (Figure 1D), 
and the incidence was 85.7% in the HCC group and 100% 
in the paracancerous group (P  > 0.05). The ampliﬁed 
fragments of HIF-1α gene were conﬁrmed by sequencing, 
and were completely consistent with the cited sequence 
of the human HIF-1α gene (Figure 2).
4.3. Expression of Circulating HIF-1α in HCC
The levels of circulating HIF-1α expression in 220 pa-
tients with liver disease are shown in Table 3. The circu-
lating HIF-1α level was increased, particularly in patients 
with chronic liver disease. If the cutoﬀ value of serum 
HIF-1α level was > 50 μg/L, the incidence of HIF-1α abnor-
mality was 100% in HCC, 89.2% in liver cirrhosis, 66.7% in 
chronic hepatitis, and none in acute hepatitis or normal 
control groups. At a cutoﬀ value of 100 μg/L, the abnor-
mality of circulating HIF-1α level was 90.8% in HCC and 
27.0% in liver cirrhosis, and none in chronic hepatitis, 
acute hepatitis, or normal control groups. The level of 
serum HIF-1α in HCC patients was signiﬁcantly higher (P 
< 0.001) than that in cases with benign liver disease. The 
evaluation of serum HIF-1α and AFP levels for HCC diagno-
sis using ROC curves is shown in Figure 3. The advantage 
of analyzing 2 markers over the whole range of sensitivi-
ties and speciﬁcities using the area (0.854 in AFP, 0.909 in 
HIF-1α) under ROC curves indicated that the abnormality 
inﬁltration in HCC (Figure 1A), whereas signiﬁcant levels 
could be seen in compressed hepatic cords and the bor-
ders of central veins in the paracancerous tissues (Figure 
1B). Moreover, the HIF-1α positive staining was signiﬁcant-
ly higher (P = 0.017) in the paracancerous group (100%, 35 
of 35) than in the corresponding HCC group (80%, 28 of 
35). The intensity of hepatic HIF-1α expression was also 
higher in the paracancerous tissues than in the HCC tis-
sues (Z = 4.728, P < 0.001, Table 2).
4.2. Expression of Total RNA and Ampliﬁcation Analysis
Hepatic total RNA was puriﬁed from human HCC or as-
sociated paracancerous tissues. The speciﬁc concentra-
tions of total RNA were 12.4 ± 7.3 μg/mg wet liver in the 
HCC group, and 53.8 ± 52.0 μg/mg wet liver in the para-
cancerous group (Figure 1C), with signiﬁcant diﬀerence 
Figure 2. Alignment of the Ampliﬁed Fragments of the HIF-1α Gene and Ho-
mology Analysis of Their Sequences
HIF-1α: the cited sequence (349 bp, nt 2452-2800) of the human HIF-1α gene 
(NM_001530); HCC, ampliﬁed fragment of HIF-1α gene from HCC tissue; Para-
HCC, ampliﬁed fragment of HIF-1α gene from associated paracancerous tis-
sues.
C
Figure 1. Immunohistochemical Staining of HIF-1α and Total RNA Levels and 
Ampliﬁcation of HIF-1α mRNA in HCC or Associated Paracancerous Tissues
Hepatic HIF-1α expression can be visualized as brown particles in the cyto-
plasm and cell membrane. A, HCC tissue; B, paracancerous tissue (S-P, origi-
nal magniﬁcation × 200); C, levels of total RNA expression in HCC or associ-
ated paracancerous tissues; D, HIF-1α mRNA was synthesized to HIF-1α cDNA 
and ampliﬁed by nested PCR (349 bp); Lines 1 and 2, ampliﬁed fragment of 
HIF-1α mRNA in HCC tissue; Lines 3 and 4, ampliﬁed fragment of HIF-1α mRNA 
in paracancerous tissue; M, DNA marker with molecular weight standard. 
HCC, hepatocellular carcinoma; Para-HCC, paracancerous tissues.825
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of serum HIF-1α level could be a useful serological marker 
for HCC diagnosis.
4.4. Expression of Circulating VEGF and Ang-2 in HCC
The levels of circulating VEGF and Ang-2 expression in 
patients with chronic liver disease are shown in Table 
4. As with circulating HIF-1α expression, the circulating 
VEGF and Ang-2 levels were increased in patients with 
chronic liver disease, particularly in HCC patients. If the 
cutoﬀ value is > 280 μg/L for VEGF and > 35 μg/L for Ang-2, 
the incidence of VEGF and Ang-2 abnormality were 87.0% 
and 94.7% in HCC, 16.2% and 2.7% in liver cirrhosis, 13.3% 
and 0% in chronic hepatitis, and none in the normal con-
trol, respectively.
4.5. Clinicopathological Features of HIF-1α Expression
The expression of HIF-1α in HCC tissues correlated closely 
with the size of tumors; the incidence was 100% (14 of 14) in 
HCC tissues in the group with samples of more than 5 cm 
diameter, and 66.7% (14 of 21) in the group with samples of 
less than 5cm diameter (P = 0.017). No signiﬁcant diﬀerence 
was found between hepatic positive HIF-1α expression and 
diﬀerentiation degree of tumor, tumor number, or HBsAg 
positivity (P > 0.05). The clinicopathological characteris-
tics of circulating HIF-1α expression in HCC patients are 
shown in Table 5. Signiﬁcant diﬀerences were found for 
high HIF-1α expression in relation to tumor size (P = 0.007) 
and HCC with extrahepatic metastasis (P < 0.001), but not 
in relation to patients’ gender, age, or AFP level (P > 0.05). 
There was a very close relationship between circulating 
Figure 3. The Relationship between Circulating HIF-1α and AFP Level and Receiver Operating Characteristic (ROC) Curves (27)
A, scatter diagram of circulating HIF-1α and AFP expression level in patients with HCC; B, ROC curves for circulating HIF-1α and AFP investigated markers 
for HCC. Sensitivity = true-positive rate; speciﬁcity = false-positive rate; and the area under the ROC curves was 0.854 for AFP and 0.909 for HIF-1α.
AB
Patients, No. HIF-1α a, μg/L Cutoﬀ Value
Range Mean ± SD > 50 μg/L, No. (%) > 100 μg/L, No. (%)
HCC a 131 57.5– 208.5 136.3 ± 28.8 131 (100) 119 (90.8)
LC a 37  39.1–123.4 84.6 ± 25.9 b 33 (89.2) 10 (27.0) b
CH a 30 38.0– 96.4 58.8 ± 14.5 c 20 (66.7) b 0 (0) b
AH a 22 33.1– 48.8 37.6 ± 5.3 d, e 0 (0) b 0 (0) b
NC a 27 20.3– 31.9 24.1 ± 3.3 f, g 0 (0) b 0 (0) b
Table 3. Quantitative Analysis of Circulating HIF-1α Level (Mean ± SD) in Patients with Liver Disease
a Abbreviations: AH, acute hepatitis; CH, chronic hepatitis; HCC, hepatocellular carcinoma; HIF-1α, hypoxia-inducible factor-1α; LC, liver cirrhosis; NC, 
normal control
b P < 0.001 vs. the HCC group
c P < 0.001 vs. the liver cirrhosis group (q = 4.39)
d P < 0.01 vs. the chronic hepatitis group (q = 3.17)
e P < 0.001 vs. the liver cirrhosis group (q = 7.31)
f P < 0.001 vs. the chronic hepatitis group (q = 5.47)
g P < 0.001 vs. the liver cirrhosis group (q = 9.99)826
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Patients, No. HIF-1α a, μg/L t value  P value
HCC a 131 136.3 ± 28.8
Sex 1.009 0.315
Male
Female
109
22
137.4 ± 28.7
130.7 ± 29.0
Age 1.702 0.091
≥ 50y
< 50y 
98
33
133.7 ± 30.1
143.2 ± 24.0
Tumor size 2.721 0.007
≥ 5.0 cm
< 5.0 cm
53
78 
144.4 ± 26.3 b
130.8 ± 29.2
AFP, μg/L 0.201 0.841
≥ 400.0
< 400.0
53
78
136.9 ± 25.8
135.9 ± 30.7
HBsAg 1.712 0.089
Positive 
Negative
100
31
137.9 ± 29.6
129.2 ± 25.5
EHT a 5.522 0.000
Yes
No 
49
82
152.5 ± 21.5 c
126.6 ± 28.3
Table 5. Pathological Characteristics of HIF-1α Levels (mean ± SD) in Sera of HCC Patients
a Abbreviations: EHT, extrahepatic metastasis; HCC, hepatocellular carcinoma; HIF-1α, hypoxia-inducible factor-1α
b P < 0.01 vs. the tumor size less than 5 cm group
c P < 0.001 vs. the non-extrahepatic metastasis group
Patients, No. VEGF a, μg/L, Mean ± SD > 280 μg/L, No (%) ANG-2 a, μg/L, Mean ± SD > 35 μg/L, No (%)
HCC a 131 462.7 ± 119.2 114 (87.0) 40.8 ± 3.5 124 (94.7)
LC a 37 216.3 ± 54.5 b 6 (16.2) a 25.5 ± 5.8 b 1 (2.7) b
CH a 30 160.9 ± 98.2 b 4 (13.3) a 20.9 ± 7.1 b 0 (0) b
NC a 27 140.9 ± 54.5 b 0 (0) a 17.4 ± 2.6 b 0 (0) b
Table 4. Levels of Circulating VEGF a and ANG-2 a Expression in Patients with Chronic Liver Disease
a Abbreviations: ANG-2, angiopoietin-2; CH, chronic hepatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; NC, normal control; VEGF, vascular 
endothelial growth factor
b P < 0.001, vs. the HCC group
HIF-1α level and VEGF (r = 0.937, P < 0.001) and Ang-2 (r = 
0.933, P < 0.001), suggesting that high expression of HIF-
1α is associated with HCC metastasis and poor prognosis.
5. Discussion
HCC is one of the most common malignant cancers 
worldwide. Multiple risk factors are associated with HCC 
disease etiology, with the highest incidence in patients 
with chronic HBV or HCV infection, although other fac-
tors such as chemical carcinogenesis, alcohol consump-
tion, exposure to dietary aﬂatoxin B1, activation of onco-
genes, and inactivation of tumor suppressor genes are 
also involved (20, 21). HCC is known to contain aberrantly 
vascularized regions characterized by severe hypoxia (22). 
Hypoxia can stimulate cell proliferation, induce angio-
genesis, and accelerate invasion, and is responsible for 
treatment resistance in HCC. Activation of oncogenes or 
inactivation of tumor suppressors can change signaling 
pathways and up-regulate HIF-1α expression, leading to 
HIF-1α activation (23, 24). In the present study, the hepatic 
expression and circulating levels of HIF-1α in patients 
with liver disease were investigated in order to elucidate 
the relationship between HIF-1α level and pathological 
characteristics, as well as the diagnosis and metastasis 
of HCC.
Under hypoxic conditions it can be stabilized, binding 
to speciﬁc sites on hypoxia-response target genes, regu-
lating proliferation on a transcriptional level, and acti-
vating the expression of many hypoxia-response genes, 
which are closely involved in energy metabolism, angio-
genesis, inﬁltration, metastasis, and prognosis (25, 26). 
The positive staining of HIF-1α was brown and granule-
like, and mainly present in the cytoplasm, with lower lev-
els in the nucleus. There were obvious diﬀerences in HIF-
1α positive expression intensity among diﬀerent areas of 
tissues. HIF-1α staining in paracancerous tissues could 
be seen at signiﬁcant levels in compressed hepatic cords 
and central veins (27). The intensity of HIF-1α expression 
was signiﬁcantly higher in paracancerous tissues than 827
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in HCC tissues, mainly due to higher levels of necrosis 
in the latter, representing that there is a very close rela-
tionship between high intensity of HIF-1α expression and 
active proliferation or a hypoxic microenvironment in 
paracancerous tissues (28).
HCC is mostly characterized by uncontrolled growth 
of tumor cells. Increasing oxygen consumption results 
in a hypoxic microenvironment. HIF-1α expression is sig-
niﬁcantly high in adjacent areas of necrosis and tumor 
inﬁltration. Many factors, such as hypoxia, oncogene 
activation, inactivation of tumor suppressors, growth 
factors, and inﬂammatory factors, can up-regulate HIF-1α 
expression, either directly or indirectly, promoting the 
transcription of more than 2% of human genes, which 
are all related to oxygen and energy metabolism (28, 29). 
Productive nucleic acid metabolism, abnormal gene ex-
pression, and development of HCC are closely associated 
with the state of the surrounding vessels and hypoxic 
conditions. The level of total RNA was obviously higher 
in paracancerous tissues than in HCC, indicating that 
HIF-1α mRNA is involved in cell proliferation, neovascu-
larization, and metastasis and could be a prime target for 
gene therapy (30, 31).
Clinical pathological features of HIF-1α expression indi-
cated that HIF-1α expression intensity and positivity rate 
were lower in HCC than in paracancerous tissues, which 
was in accordance with total RNA (32). HIF-1α positivity 
rate was associated with tumor diameter, because they 
were usually single, enveloped, and well-diﬀerentiated, 
and there were more diplonts and less heteromorphism 
when tumors were small. When tumors increase in size, 
the biological characteristics changed to the contrary, in-
vasion is therefore strengthened, and tumor blood sup-
ply cannot satisfy growth demand (33, 34). HBx and HIF-
1α are both present in the cytoplasm in HCC. Moreover, 
HBx can up-regulate HIF-1α under normoxic or hypoxic 
conditions, reinforce HIF-1α transcriptional activity via 
the MAPK pathway, increase HIF-1α protein levels, induce 
neovascularization, and thus contribute to metastasis 
(32). In the present study, no correlation was found be-
tween HIF-1α and HBsAg positivity in HCC and further 
studies are required to determine whether HIF-1α is as-
sociated with HBV.
The prognosis for HCC is poor, and early detection is 
of the utmost importance. Treatment options are se-
verely limited by the frequent presence of metastases. 
Although the mechanisms of hepatocarcinogenesis 
have not been elucidated, a long-lasting inﬂammation 
induced by hepatitis virus infection is a deﬁnite risk for 
neoplastic degeneration and the accumulation of ge-
netic alterations (35, 36). Serum AFP is a useful serologi-
cal marker for monitoring HCC development; however, a 
high false negative rate has been found when using AFP 
level alone for monitoring small HCCs (37). Fragments of 
circulating HIF-1α could be detected in all patients with 
HCC with extrahepatic metastasis; as with circulating 
IGF-II, these results argue for growth factor-dependent 
HCC development and could provide novel markers of 
severity and prognosis for HCC. The present data indicate 
that expression of serum HIF-1α, Ang-2, and VEGF can only 
be detected in the peripheral blood of patients with HCC. 
The frequency of circulating HIF-1α and its diagnostic val-
ue increases with distal metastases of HCC hepatocytes 
(38). The pathological characteristics of serum HIF-1α 
were associated with the levels of circulating VEGF and 
Ang-2, the size of the tumor, and extrahepatic metastasis, 
and but not with patients’ gender, age, and AFP level.
In conclusion, hepatic HIF-1α expression is associated 
with the development and prognosis of HCC, and circu-
lating HIF-1α level is a useful molecular marker in HCC di-
agnosis, and for monitoring prognosis. HIF-1α expression 
in hepatic tissues plays an important role in the develop-
ment and prognosis of HCC. HIF-1α, as an initial hypoxia 
moderator, should be a promising molecular target for 
the development of anti-HCC agents (39). The intensity of 
HIF-1α expression was signiﬁcantly higher in paracancer-
ous tissues than in HCC, mainly due to higher necrosis 
in the latter, representing the likelihood that there is a 
very close relationship between a high intensity of HIF-1α 
expression and active metabolism or hypoxic microen-
vironment in paracancerous tissues; HIF-1α could there-
fore be a useful molecular target for gene therapy.
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